Table 3

Characteristics of patients without germline mutation with tumours showing loss of MS2, MSH6 or isolated loss of PMS2

Patient	Sex	Age	Site of CRC	Amsterdam	Bethesda	MSI	Protein loss
1	F	79	Caecum	No	No	Yes	MSH2/MSH6
2	M	69	Rectum	No	No	Yes	MSH2/MSH6
3	F	69	Rectum	No	Yes	Yes	MSH2/MSH6
4	F	65	Transverse	No	No	Yes	MSH2/MSH6
5	M	57	Transverse	No	No	Yes	MSH2/MSH6
6	M	66	Rectum	No	No	Not available	MSH2/MSH6
7	F	89	Ascending	No	Yes	No	MSH2/MSH6
8	M	60	Rectum	No	No	No	MSH2
9	F	67	Caecum	No	No	No	MSH2
10	M	66	Descending	No	No	Yes	MSH2/MSH6
11	F	57	Ascending	No	Yes	Yes	MSH2/MSH6
12	F	72	Rectum	Yes	Yes	Yes	MSH2/MSH6
13	M	58	Descending	No	Yes	Yes	MSH2/MSH6
14	M	67	Sigmoid	No	Yes	No	MSH2
15	M	64	Rectum	No	No	No	MSH2
16	M	73	Hepatic flexure	No	No	Yes	MSH2/MSH6
17	F	52	Sigmoid	No	No	Yes	MSH2/MSH6
18	F	62	Rectum	No	Yes	Yes	MSH2/MSH6
19	M	59	Rectum	No	No	No	MSH2/MSH6
20	M	32	Rectum	No	Yes	Yes	MSH2/MSH6
21	M	32	Ascending	Yes	Yes	Yes	MSH2/MSH6
22	F	74	Transvers	No	No	Yes	MSH2/MSH6
23	M	38	Sigmoid	No	Yes	Yes	MSH2/MSH6
24	M	63	Sigmoid	No	Yes	Yes	MSH6
25	F	55	Hepatic flexure	No	Yes	Yes	MSH6
26	M	85	Rectum	No	No	No	MSH6
27	M	85	Hepatic flexure	No	No	Yes	MSH6
28	F	56	Transverse	No	Yes	Yes	MSH6
29	F	83	Rectum	No	Yes	Yes	MSH6
30	F	78	Sigmoid	No	Yes	Not available	MSH6
31	M	55	Rectum	No	Yes	No	MSH6
32	F	77	Sigmoid	No	No	Yes	PMS2
33	M	72	Descending	No	No	Yes	PMS2

CRC, colorectal cancer; F, female; M, male; MSI, microsatellite instability.